Improvement of the Antitumor Activity of Intraperitoneally and Orally Administered 5,6-Dimethylxanthenone-4-Acetic Acid by Optimal Scheduling

Clinical Cancer Research

Volumn 9, Issue 17, 2003, Pages 6545-6550

  Zhao, Liangli ^a   Ching, Lai Ming ^a   Kestell, Philip ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; COLON TUMOR; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CELL LINE, TUMOR; CLINICAL TRIALS; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TIME FACTORS; XANTHONES;

EID: 0346963094     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rewcastle, G. W., Atwell, G. J., Zhuang, L., Baguley, B. C., and Denny, W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem., 34: 217-222, 1991.
2. Jameson, M. B., Thompson, P. I., Baguley, B. C., Evans, B. D., Harvey, V. J., Porter, D. J., McCrystal, M. R., Small, M., Bellenger, K., Gumbrell, L., Halbert, G. W., and Kestell, P. Phase I trial of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Br. J. Cancer, 88: 1844-1850, 2003.
3. Rustin, G. J., Bradley, C., Galbraith, S., Stratford, M., Loadman, P., Waller, S., Bellenger, K., Gumbrell, L., Folkes, L., and Halbert, G. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br. J. Cancer, 88: 1160-1167, 2003.
4. Zwi, L. J., Baguley, B. C., Gavin, J. B., and Wilson, W. R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res., 6: 79-85, 1994.
5. Lash, C. J., Li, A. E., Rutland, M., Baguley, B. C., Zwi, L. J., and Wilson, W. R. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer, 78: 439-445, 1998.
6. Galbraith, S. M., Rustin, G. J., Lodge, M. A., Taylor, N. J., Stirling, J. J., Jameson, M., Thompson, P., Hough, D., Gumbrell, L., and Padhani, A. R. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol., 20: 3826-3840, 2002.
7. Ching, L. M., Goldsmith, D., Joseph, W. R., Korner, H., Sedgwick, J. D., and Baguley, B. C. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res., 59: 3304-3307, 1999.
8. Zhao, L., Ching, L. M., Kestell, P., and Baguley, B. C. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer, 87: 465-470, 2002.
9. Jameson, M. B., Thompson, P. I., Baguley, B. C., Evans, B. D., Harvey, V. J., Porter, D. J., McCrystal, M. R., and Kestell, P. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc. Am. Soc. Clin. Oncol., 19: 182a, 2000.
10. Philpott, M., Joseph, W. R., Crosier, K. E., Baguley, B. C., and Ching, L-M. Production of tumour necrosis factor-α by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br. J. Cancer, 76: 1586-1591, 1997.
11. Baguley, B. C. Antivascular therapy of cancer: DMXAA. Lancet Oncol., 4: 141-148, 2003.
12. Philpott, M., Baguley, B. C., and Ching, L-M. Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol., 36: 143-148, 1995.
13. Zhao, L., Kestell, P., Ching, L-M., and Baguley, B. C. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. Cancer Chemother. Pharmacol., 49: 20-26, 2002.
14. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
15. Gately, S., and Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J., 7: 427-436, 2001.
16. Kestell, P., Zhao, L., Baguley, B. C., Palmer, B. D., Muller, G., Paxton, J. W., and Ching, L. M. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-actic acid (DMXAA) in mice by thalidomide. Cancer Chemother. Pharmacol., 46: 135-141, 2000.
17. Zhao, L., Kestell, P., Philpott, M., Ching, L-M., Zhuang, L., and Baguley, B. C. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol., 47: 491-497, 2001.
18. Holford, N. H. G. MKMODEL, a modelling tool for microcomputers: a pharmacokinetic evaluation and comparison with standard computer programs. Clin. Exp. Pharmacol. Suppl., 9: 95, 1985.
19. Philpott, M., Ching, L. M., and Baguley, B. C. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator to other inducers of tumour necrosis factor. Eur. J. Cancer, 37: 1930-1937, 2001.
20. Karin, M., and Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol., 18: 621-663, 2000.
21. Laws, A. L., Matthew, A. M., Double, J. A., and Bibby, M. C. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer, 71: 1204-1209, 1995.